A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality

Canopy Growth

Status and phase: Completed; Phase 2; Phase 1

Conditions: Healthy Adults

Treatments: Dietary Supplement: CBN and CBD

Study type: Interventional

Funder types: Industry

Identifiers

NCT05839964

710US-1501

Details and patient eligibility

About

This is a randomized, double-blind, placebo-controlled, study to assess the safety and effects of CHI-560, CHI-563, CHI-564, & CHI-565 versus placebo on sleep quality in healthy adult participants ages 18-55 years.

Enrollment: 301 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Person is between 18 and 55-years-old (inclusive).
2. Person has a BMI between 18 and 35 kg/m2 (inclusive).
3. Person is willing and able to provide informed consent.
4. Woman of childbearing potential must not be pregnant or currently breastfeeding.
5. Person agrees to abide by all study restrictions and comply with all study procedures.
6. Person rates past-week sleep quality on a 1 (very poor) to 5 (very good) rating scale as poor (2) or very poor (1).

Exclusion criteria

1. Person has a known history of significant allergic condition, significant hypersensitivity to the IP, or allergic reaction to cannabis, cannabinoid medications, hemp products, or excipients of the IP.
2. Person has been exposed to any investigational drug or device < 30 days prior to screening or plans to take an investigational drug in the near future (within 30 days).
3. Person has had a change in allowable medication, caffeine, tobacco, alcohol, supplement, or other drug use dose or regimen within 30 days of screening or has any plans to change dose or regimen during the course of the study.
4. Person has used cannabis, cannabinoid analogue (e.g., dronabinol, nabilone), and/or any CBD- or delta-9-tetrahydrocannabinol (THC)-containing product within 30 days of screening or during the study.
5. Person has history of use of any synthetic cannabinoid receptor agonist (e.g., spice, K2) within the past year.
6. Person is currently using products or medications that may interact with one or more of the ingredients in the IP, including the following drugs or supplements: warfarin, clobazam, valproic acid, phenobarbital, mechanistic target of rapamycin [mTOR] inhibitors, oral tacrolimus, St. John's wort, and Epidiolex.
7. Person has a positive screen (i.e., exceeds cut-point score) for any of the following sleep disorders on the Sleep Disorders Symptom Checklist-17 (SDS-CL-17): narcolepsy, obstructive sleep apnea, restless legs syndrome.
8. Person has a personal or family history (first-degree relative) of a psychotic disorder and/or schizophrenia.
9. Person endorses current suicidal intent as indexed via items 4 and 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS).
10. Person has an acute or progressive disease or disorder that is likely to interfere with the objectives of the study, or the ability to adhere to protocol requirements.
11. Person has a history of cardiovascular disease.
12. Woman of childbearing potential, unless she has not engaged in vaginal intercourse or she has used effective contraception when doing so (for example, oral contraception, double barrier, intra-uterine device) for at least 30 days prior to the study.
13. Woman of childbearing potential, unless willing to ensure that she or her partner use effective contraception (for example, oral contraception, double barrier, intra-uterine device) during the study and for 30 days thereafter (however, a male condom should not be used in conjunction with a female condom).
14. Man whose partner is of childbearing potential, unless willing to ensure that he or his partner use effective contraception (for example, oral contraception, double barrier, intra-uterine device) during the study and for 30 days thereafter (however, a male condom should not be used in conjunction with a female condom).
15. Person has history of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase [ALT] >5 ⋅ upper limit of normal [ULN] or total bilirubin [TBL] >2 ⋅ ULN) OR the ALT or aspartate aminotransferase (AST) >3 ⋅ ULN and TBL >2 ⋅ ULN (or international normalized ratio [INR] >1.5).
16. Person demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

301 participants in 5 patient groups, including a placebo group

CHI-560: Total daily dose: 20 mg CBN

Active Comparator group

Description:

2 units (i.e., 2 gummies). Each gummy: 10 mg CBN

Treatment:

Dietary Supplement: CBN and CBD

CHI-563: Total daily dose: 20 mg CBN + 10 mg CBD

Active Comparator group

Description:

2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 5 mg CBD

Treatment:

Dietary Supplement: CBN and CBD

CHI-564: Total daily dose: 20 mg CBN + 20 mg CBD

Active Comparator group

Description:

2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 10 mg CBD

Treatment:

Dietary Supplement: CBN and CBD

CHI-565: Total daily dose: 20 mg CBN + 100 mg CBD

Active Comparator group

Description:

2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 50 mg CBD

Treatment:

Dietary Supplement: CBN and CBD

CHI-660: Placebo

Placebo Comparator group

Description:

2 units (i.e., 2 gummies). Each gummy: Placebo

Treatment:

Dietary Supplement: CBN and CBD